Smartleaf Asset Management LLC Increases Position in Sanofi (NASDAQ:SNY)

Smartleaf Asset Management LLC increased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 167.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 9,303 shares of the company's stock after purchasing an additional 5,819 shares during the period. Smartleaf Asset Management LLC's holdings in Sanofi were worth $449,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SNY. Farther Finance Advisors LLC increased its position in shares of Sanofi by 12.1% during the third quarter. Farther Finance Advisors LLC now owns 2,861 shares of the company's stock worth $165,000 after acquiring an additional 309 shares during the period. QRG Capital Management Inc. increased its holdings in Sanofi by 8.7% during the 3rd quarter. QRG Capital Management Inc. now owns 152,406 shares of the company's stock worth $8,783,000 after purchasing an additional 12,245 shares during the period. PDS Planning Inc raised its position in Sanofi by 3.1% in the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company's stock valued at $383,000 after purchasing an additional 200 shares in the last quarter. HF Advisory Group LLC boosted its stake in shares of Sanofi by 5.5% in the 3rd quarter. HF Advisory Group LLC now owns 28,763 shares of the company's stock valued at $1,658,000 after buying an additional 1,487 shares during the period. Finally, Harvest Portfolios Group Inc. grew its position in shares of Sanofi by 4.2% during the third quarter. Harvest Portfolios Group Inc. now owns 37,200 shares of the company's stock worth $2,144,000 after buying an additional 1,500 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on SNY. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $60.00.

Sanofi Stock Performance

SNY traded up $1.45 on Wednesday, reaching $59.15. The company had a trading volume of 3,617,481 shares, compared to its average volume of 2,510,160. The stock has a 50-day moving average price of $52.22 and a 200-day moving average price of $52.68. The stock has a market capitalization of $150.11 billion, a PE ratio of 23.76, a P/E/G ratio of 1.01 and a beta of 0.57. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 1 year low of $45.22 and a 1 year high of $59.19.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.